Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott Amidate shortage

Executive Summary

Abbott files sNDA requesting approval for use of alternate supplier for Amidate active ingredient etomidate. Company announces shortage of anesthetic in June 18 "Dear Clinician" letter. "Our approved supplier of the active pharmaceutical ingredient has exited the market," letter says. "Clinicians are requested to utilize Amidate judiciously for the interim period of time until Abbott is able to manufacture sufficient inventory to once again meet the market demands." Shortages of another anesthetic, fentanyl, prompted Abbott to double its own production last year (1"The Pink Sheet" March 21, 2001, p. 16)...

You may also be interested in...

Abbott Doubles Fentanyl Production To Address Hospital Shortages

Abbott has doubled the production of fentanyl to respond to supply shortages of the anesthetic in hospitals around the country, the company said.

Health Sector On High Alert As Wuhan Coronavirus Spreads

The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”

OTC Drug Oversight By US FDA Split Among Two Divisions In Reorganization

CDER Office of New Drugs changes its organization including establishing Office of Nonprescription Drugs and splitting the office into Division of Nonprescription Drug Products I and DNDP II. A Division of Regulatory Operations for Nonprescription Drugs will be comprised of regulatory staff from the ONPD divisions and will report to OND’s regulatory office. Non-clinical ONPD staff will report to the office director.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts